NeurAxis (NRXS) reported a third-quarter loss of $0.52 per share, well wide of the -$0.21 consensus. That is a 147.6% negative surprise, and per-share earnings fell 116.7% year over year. Revenue of $2.03 million rose 150.1% from a year ago but missed the $2.1 million consensus by 3.4%. The headline miss is less damaging than it looks, and the revenue story is better than the shortfall suggests. The real problem sits on the balance sheet. That is the central tension: the commercial model is finally working after the Category I CPT code took effect, but the company is spending faster than it promised to fund that growth, with a thin cash cushion.

The quality of the earnings miss deserves context. General and administrative expense jumped to $7.0 million from $1.9 million, driven mainly by $4.3 million of one-time, non-recurring stock compensation charges tied to the net settlement of restricted stock units issued when options were canceled. That pushed the GAAP operating loss to roughly $6.6 million and the net loss to $6.5 million, versus $2.1 million a year earlier. Strip out the charge and the adjusted operating loss was about $2.3 million, up 9% year over year. That is not a blowout, but it is not a collapse either. Gross margin is the cleaner signal. It expanded 330 basis points to 86.6% as more devices were sold at full reimbursement rather than through the discounted financial-assistance program. Average selling price climbed to $1,045 from $992 in the second quarter.

The call showed broad operating improvement. Revenue growth has accelerated for four straight quarters: from 27% in Q4 2025 to 80%, then 116%, and now 150%. Unit growth stepped up from 32% to 60% to 92%. Two large national payers, identified in Q&A as Cigna and Aetna, added roughly 44 million lives in the past 45 days, lifting covered lives to about 147 million from 101 million. The year-to-date prior-authorization approval rate reached 38% as of October 30, against 12% for all of 2025. Ordering accounts rose to 97, and year-to-date revenue per account jumped to $57,000 from $40,000. Management's tone was notably more confident, with talk of a "significant windfall" in 2027 from the new payers.

Bears still have legitimate ammunition. Sequential revenue growth was only about 4%, from roughly $1.93 million in Q2 to $2.0 million, so the year-over-year acceleration partly reflects an easy comparison. The new-payer benefit is also arriving more slowly than coverage headlines imply. One major payer's third-party prior-auth vendor approved only one of four devices, which pushed that contribution into the fourth quarter. Incomplete Medicaid fee-schedule implementation is also still slowing account activation. Only 27 states list the code, and the CEO is targeting about 90% by spring or mid-2027. Catalysts include:

• a new Chief Commercial Officer and VP of Market Access;
• at least five new territories;
• a VA independent-rep model;
• an October digital campaign;
• retroactive resubmission of previously denied patients;
• an adult functional dyspepsia trial of 300-plus patients that is nearing enrollment.

All of that costs money. Free cash outflow was $2.3 million in the quarter, more than double Q2's $1.0 million, even though the Q1 call had guided to $1 million or less per quarter. Cash fell to $4.5 million from $8.3 million, partly on RSU withholding taxes. The company reactivated its at-the-market facility, raising about $1.7 million after quarter-end, and going-concern language remains. Management also signaled that SG&A and burn will rise further near term and deferred any profitability discussion to the first half of 2027. No formal financial guidance was offered.

Investor sentiment heading into the report was deeply negative, at -0.86 on the -1 to +1 scale, so expectations were already depressed. Shares closed at $6.24 on November 6. That is up 3.1% from the $6.05 open after the August report, but 6.9% below the $6.70 200-day moving average. The inter-earnings range was violent: a $5.31 low on September 14 and an $8.06 high just three days later. The stock now sits about 22.6% below that high and 17.5% above the low, which shows how quickly speculative enthusiasm has come and gone. Earnings Whispers sequential-growth and momentum trends are positive, while the AVWAP trend remains negative. That mix fits a stock with improving operations but an unresolved overhang.

The bottom line is that NeurAxis delivered the clearest evidence yet that CPT-driven coverage is translating into units, pricing, and margin. However, the GAAP miss and the doubling of cash burn shift the debate from demand to funding. With $4.5 million in the bank and spending rising, investors will need to see the new payers and Medicaid states convert into sequential revenue growth quickly enough to limit further dilution.